Guardant Health, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
GH$155.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share data)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $989,291 | $378,203 |
| Short-term marketable securities | 113,469 | 823,395 |
| Accounts receivable, net | 137,404 | 137,849 |
| Inventory, net | 83,851 | 85,876 |
| Prepaid expenses and other current assets, net | 43,490 | 40,723 |
| Total current assets | 1,367,505 | 1,466,046 |
| Restricted cash | 112,150 | 111,214 |
| Property and equipment, net | 150,035 | 145,915 |
| Right-of-use assets, net | 153,906 | 158,849 |
| Intangible assets, net | 25,543 | 25,921 |
| Goodwill | 77,257 | 77,257 |
| Other assets, net | 28,895 | 28,457 |
| Total Assets | $1,915,291 | $2,013,659 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $75,034 | $54,442 |
| Accrued compensation | 91,326 | 119,646 |
| Accrued expenses | 78,013 | 77,889 |
| Deferred revenue | 47,772 | 50,753 |
| Total current liabilities | 292,145 | 302,730 |
| Convertible senior notes, net | 1,503,471 | 1,504,000 |
| Long-term operating lease liabilities | 173,055 | 178,463 |
| Other long-term liabilities | 127,693 | 127,773 |
| Total Liabilities | 2,096,364 | 2,112,966 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ deficit: | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 131,514,404 and 130,635,301 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 2,930,665 | 2,900,056 |
| Accumulated other comprehensive loss | (5,152) | (4,852) |
| Accumulated deficit | (3,106,587) | (2,994,512) |
| Total Stockholders’ Deficit | (181,073) | (99,307) |
| Total Liabilities and Stockholders’ Deficit | $1,915,291 | $2,013,659 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.